Clinical Drug Investigation

• Suitability Profiles of Ibuprofen and Paracetamol Patient selection can limit the generalizability of a study, so the findings of the 1999 PAIN study should be interpreted cautiously.
  Clinical Drug Investigation™, October 01, 2006
• Treatment of Aphthous Stomatitis with Topical Alchemilla vulgaris Aphtarine gel is a safe, well tolerated and effective new treatment for healing common mouth ulcers.
  Clinical Drug Investigation™, October 01, 2006
• Resource and Time Commitment of Treating Anemia in Cancer Patients The amount of time and the costs involved in treating cancer-induced anemia can be significant and should be weighed when choosing a treatment plan.
  Clinical Drug Investigation™, October 01, 2006
• Treating Chronic Constipation: How Should We Interpret the Recommendations? This review can help clinicians interpret and apply new guidelines on diagnosing and treating chronic constipation.
  Clinical Drug Investigation™, October 01, 2006
• Synergistic Effect of Doxazosin and Acarbose in Improving Metabolic Control Doxazosin given in combination with acarbose seemed to improve both glycemic and lipid control, with benefits extending beyond those expected from improvements in blood pressure.
  Clinical Drug Investigation™, September 01, 2006
• Impact of SOJA Methodology on Prescribing Costs of ACE Inhibitors Hospitals use this structured approach to select drugs for formularies, and a modified approach can help control costs across secondary and primary care.
  Clinical Drug Investigation™, September 01, 2006
• Efficacy and Tolerability of Moxifloxacin for Respiratory Tract Infections This novel fluoroquinolone was highly rated by both physicians and patients for its rapid symptom improvement and good tolerability.
  Clinical Drug Investigation™, September 01, 2006
• Dexketoprofen Trometamol vs Ketoprofen in the Management of Pain The 2 medications were equivalent in terms of analgesic activity, but the high use of rescue analgesics indicates a need for a multimodal approach to pain management.
  Clinical Drug Investigation™, September 01, 2006
• Cost-Effectiveness Analysis of Schizophrenia Relapse Prevention Ziprasidone therapy avoids a considerable number of relapses at a reasonable cost, producing cost savings.
  Clinical Drug Investigation™, August 01, 2006
• Blood Pressure Self-Measurement and Blood Pressure Reduction Patients who regularly measured and recorded their blood pressure at home had a better response to treatment with olmesartan medoxomil.
  Clinical Drug Investigation™, October 23, 2006
• Drug-Related Problems in the Community Setting Pharmacists conducting home medication reviews for mentally ill patients identified a high incidence of drug-related problems.
  Clinical Drug Investigation™, July 01, 2006
• Experience With the Novopen Family of Insulin Injection Devices Published studies over the past two decades demonstrate the patient-related benefits of these pen injection devices.
  Clinical Drug Investigation™, July 01, 2006
• Long-Term Safety of Intravenous Ibandronic Acid This bisphosphonate appears to be well tolerated over the long term, making it an important new treatment option for the management of metastatic bone disease.
  Clinical Drug Investigation™, June 01, 2006
• Low-Molecular-Weight Heparin for Acute STEMI Parnaparin sodium, a LMWH, was more effective than UFH in reducing composite cardiac events in patients with STEMI following thrombolytic therapy.
  Clinical Drug Investigation™, June 01, 2006
• Montelukast Decreases ET-1 and ECP Levels in Pediatric Asthma Monitoring ET-1 and ECP levels in combination with spirometry at regular follow-up may be useful in assessing chronic inflammation in bronchial asthma.
  Clinical Drug Investigation™, June 01, 2006
• Impact of Influenza Treatment With Oseltamivir Early treatment with this potent antiviral drug not only reduces the duration and severity of influenza symptoms, it also may help reduce the overall burden of influenza on society.
  Clinical Drug Investigation™, June 01, 2006
• Lornoxicam Quick-Release Compared With Diclofenac Potassium Quick-release lornoxicam, a potent NSAID, offers faster pain relief and is more effective on most measures than an equivalent formulation of diclofenac potassium.
  Clinical Drug Investigation™, June 01, 2006
• A Phase I Study of Dose-Dense Topotecan in SCLC Patients Topotecan appears to be well suited for dose-dense induction therapy in patients with SCLC, and a phase II trial is already underway.
  Clinical Drug Investigation™, June 01, 2006
• SSRIs in the Treatment of Depression in Children and Adolescents Despite many conflicting reports on this issue, SSRIs remain a first-line pharmacological treatment for this group of patients. However, careful monitoring and further study still are needed.
  Clinical Drug Investigation™, June 01, 2006
• Tanacetum parthenium and Salix alba for Migraine Prophylaxis This over-the-counter therapy demonstrated remarkable efficacy in reducing the frequency, intensity, and duration of migraines, warranting further study.
  Clinical Drug Investigation™, June 01, 2006